CP 80633

Pricing Availability Delivery Time Qty
Cat.No. 2729 - CP 80633 | C18H24N2O3 | CAS No. 135637-46-6
Description: Selective PDE4 inhibitor
Chemical Name: 5-[3-[(1S,2S,4R)-Bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl]tetrahydro-2(1H)-pyrimidinone
Purity: ≥99% (HPLC)
Datasheet
Citations
Literature

Biological Activity

Selective inhibitor of phosphodiesterase type 4 (IC50 values are 1.9, > 100, > 100, > 100 and > 100 μM for human lung PDE4, lung PDE1, lung PDE2, heart PDE3 and platelet PDE-V respectively) that displays no significant PDE4 isozyme selectivity. Inhibits hydrolysis of cAMP in isolated human peripheral blood monocytes, eosinophils and T cells.  Displays anti-inflammatory and bronchodilatory effects in vivo.

Technical Data

M. Wt 316.39
Formula C18H24N2O3
Storage Store at +4°C
Purity ≥99% (HPLC)
CAS Number 135637-46-6
PubChem ID 9861730
InChI Key LITNEAPWQHVPOK-FFSVYQOJSA-N
Smiles O=C(NC4)NCC4C1=CC(O[C@H]2C[C@@H]3CC[C@H]2C3)=C(OC)C=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 31.64 100
ethanol 31.64 100

Preparing Stock Solutions

The following data is based on the product molecular weight 316.39. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.16 mL 15.8 mL 31.61 mL
5 mM 0.63 mL 3.16 mL 6.32 mL
10 mM 0.32 mL 1.58 mL 3.16 mL
50 mM 0.06 mL 0.32 mL 0.63 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Safety Datasheet

References

References are publications that support the products' biological activity.

Turner et al (1996) The in vivo pharmacology of CP-80,633, a selective inhibitor of phosphodiesterase 4. J.Pharmacol.Exp.Ther. 278 1349 PMID: 8819522

Cohan et al (1996) In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633. J.Pharmacol.Exp.Ther. 278 1356 PMID: 8819523

Cheng et al (1997) The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-α (TNFα) production in mice: effect of adrenalectomy. J.Pharmacol.Exp.Ther. 280 621 PMID: 9023272


If you know of a relevant reference for CP 80633, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Phosphodiesterase Inhibitors

Keywords: CP 80633, supplier, Selective, PDE4, inhibitors, inhibits, Phosphodiesterases, CP80633, Phosphodiesterases, Tocris Bioscience

Citations for CP 80633

Citations are publications that use Tocris products.

Currently there are no citations for CP 80633. Do you know of a great paper that uses CP 80633 from Tocris? If so please let us know.

Commented out for usability testing

Reviews

TODO: Add Reviews

Literature in this Area

Cardiovascular

Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure
Asthma

Asthma Poster

Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. This poster highlights key pathways and new therapies used to treat the condition, including those currently in clinical development.

Pathways for CP 80633

Protocols

TODO: Add Protocols